4th China Pharma IP Summit 2019，Oct 23-25,Shanghai China

Vapor

2019-07-08 09:57:13

英2.jpg

4th China Pharma IP Summit 2019 (CPIPS2019) organized by Shanghai YIP Events, Supported by Pharma IP Right Research Committee of Chinese Pharmaceutical Association , which will be held on 23rd -25th , Oct this year at Primus Hotel Shanghai Hongqiao China.

As a dedicated event to pharmaceutical intellectual property, In the past three years CPIPS has gathered more than 1000 attendees from relevant government departments(CNIPA/EPO/JPO/USPTO), industry associations, global and china local pharma/biotech companies, law firms, IP agencies, IP solution providers and so on. CPIPS topics covered the IP protection and hot issues in all over the world, include mainly China, Europe, US, Japan, South Korea and India. CPIPS is currently the best and largest Pharma IP focused event in China, this year CPIPS will attract more than 500 pharma IP peers from all over the world.

Hot Topics that will be Presented and Discussed :

Drug Regulatory Updates and Outlook in China
Examination of Invalidation Cases and Practice of Pharma Compound Patent Examination
Patent Linkage, Patent Term Restoration in China
Identification and Persuasion Strategy of Technical Facts in Pharma Patent Cases
Data Supplementation for Chemical and Biotech Patents
Trade (Technical) Secret Infringement and Protection of the Pharma Industry
Patent Protection of Biological Sequences
Evaluation of Inventive Step of Pharmaceutical Compound Inventions
Latest Developments of IPR and Recent Patent Invalidation Cases
The Strategy of ANDA Filers to Challenge Patents Under a PIV Certification and Recent ANDA Litigation Cases Study
Identifying the Loss of Exclusivity (LoE) of a U.S. Pharmaceutical Patent Portfolio
U.S. Biosimilar Patent Litigation: Strategies and Trends
Oncology IP Portfolio Development and Strategy and Implications Under the Current US-China Politic/Economic Environment
UPC and UPS - Why does it Make Sense for Europe and What Could be the Impact of Brexit?
Recent European Regulatory Developments on Supplementary Protection Certificates (SPCs)
How to Build a Successful Licensing Program and Other Strategies for IP Monetization
Panel Discussion: Global Patent Issues of Therapeutic Antibodies
Biosimilars in US,EU and China: Where Are We Now and Where Are We Going?
Patent System and Practice of Medical Fields and Patent Term Extension in Japan
IP Management & Practices Adopted by Generic Drug Manufacturers from India
Patent System for Pharmaceutical Invention
Life Sciences: IP and Regulatory Environment in Brazil and selected Latin American Jurisdictions
Expanding International Business :Strategy to Grow and Optimize Generic Portfolio in New Geographies (ROW countries)
Patenting Situation of TCM and Studies from Invalidation Cases
Rethinking of Patent Creative Evaluation for Traditional Chinese Medicine
Protect the Technologies from Traditional Chinese Medicine: Challenges and Opportunities
IP Challenges and Strategy for Traditional Chinese Medicine ‘Going Out’

Confirmed Speakers as of June 30th :

Qingkui Zhang,Honorary Director,Pharma IP Right Research Committee
Qiujuan Ma,Director of Pharmaceutical Division,Patent Examination Cooperation (Beijing) Center of The Patent Office,CNIPA New
Jiangming Wu,Deputy Director,Patent Examination Cooperation Jiangsu Center of The Patent Office, CNIPA New
Peter Storm, Senior Patent Attorney, AstraZeneca New
Lareina Chen,IP Manager,Shanghai Junshi Biosciences New
Songyan Rui,Judge, Beijing Intellectual Property Court New
Bo Xu, Judge, Beijing Intellectual Property Court New
Hou Yao, Researcher, Reexamination and Invalidation Department of the Patent Office, CNIPA
Xiangjun Li,Vice President,SHIJIAZHUANG YILING PHARMACEUTICAL New
Yongshun Cheng,Director,Beijing Intellectual Property Institute
Yang Xu, Patent Attorney, BeiGene, Ltd.
Wenjun Geng,IP Director,CHIA TAI TIANQING PHARMACEUTICAL GROUP
Lifang Sun, IP Vice President,Luye Pharma Group New
Nick Qinghui Liu,Partner,Anjie Law Firm
Xiaoting Song,Professor, Tongji University New
Caihui Li,Senior IP Director, 3SBio Group New
Bo Xu, Judge, Beijing Intellectual Property Court New
Feng Xu, IP Director for China and Asia, AstraZeneca
Wu Li,Partner, Anjie Law Firm
Wenping Chen, Partner, King & Wood Mallesons New
Tina Tai, Partner,King & Wood Mallesons New
Michael Wise, Partner, Perkins Coie LLP New
Shashank Upadhye, Partner, Upadhye Cwik LLP
Carl A. Morales, Partner, Dechert LLP New
Gang Wang, Associate, Dechert LLP New
Xiarui Dou, IP Director,Yabao Pharmaceutical Group New
Yite John Lu, Partner, Irell & Manella LLP New
Andy Zhang,Senior Corporate Counsel, Intellectual Property, Sunovion Pharmaceutical New
Teresa Lavoie,Principal, Fish & Richardson P.C. New
Dr. Joerg Thomaier, Head of IP, Bayer Group New
Wanli Tang, Associate, Jones Day
Tony Chen,Partner,Jones Day
Bharati Nadkarni, Vice President Portfolio Planning and IP litigation,Sun Pharmaceutical New
Yehudah Livneh, Former General Patent Counsel and VP Corporate IP , Teva Pharmaceuticals New
Chris Goddard, Partner, Dehns Patent and Trade Mark Attorneys New
Toru Matsuoka, Deputy Director, Examination Standards Office,JPO New
Poonam Raghuvanshi, Vice President & Head of IP, Dr. Reddy's Laboratories Ltd. New
Ilseok Alban Kang, Patent Attorney, FirstLaw P. C. New
Gustavo Morais, Partner,IP Agent, Dannemann Siemsen New
Ana Carneiro, Partner, IP Agent, Dannemann Siemsen New
Yongfeng Zheng,Legal Director and Vice Dean of Research Institute, Tasly Holding Group New
Peter L. Dolan,Strategy and Business Development Senior Director,Sanofi
Dr. Christof Bull,Associate General Patent Counsel,UCB Biopharma
Daisy Wu, IP Director,Shanghai Henlius Biotech,Inc. New
Mahendra B. Thakre，Senior General Manager, Global IP, Mylan Laboratories Limited